OakChart

Surrozen Inc

SRZNHealthcare·Biotechnology·USA·Small·NASD·Nov 11 • 3:59 PM ET

31.88-0.76 (-2.33%)
2026-11-12 05:56 CET
Market cap
374.70 USD m
Revenue, TTM
10.53 USD m
Net income, TTM
-408.35 USD m
Free cash flow, TTM
-30.77 USD m
EPS diluted, TTM
-46.94
P/E
-
Compare

Price

SRZN against its 20, 50 and 200-day averages
2050200beatmiss
15.0020.0025.0030.0035.005.8M11.5MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26SRZNclose 31.8820-day 28.3550-day 25.54200-day 25.5431.8852w high

15.7% under the 52-week high of 37.83 on 25 Sep 2026. 52-week low 11.73 on 11 Nov 2025. Last 15 sessions, 37.4% high to low

Volume 0.29× normal · the line is the 50-bar volume average

Profile

SRZN
52-week range, 77% of the way up
11.7337.83

Surrozen, Inc. is a clinical stage biotechnology company, which engages in the business of discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. The company was founded by K. Christopher Garcia and Roeland Nusse on August 12, 2015 and is headquartered in South San Francisco, CA.

IndexRUT
Employees44
IPOJan 11, 2021
Beta0.54
ATR, 14d2.45
Rel volume0.29
Short float32.74%
Insider own48.17%
Inst own74.23%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap607.68M
Enterprise Value513.17M
Income-408.35M
Sales10.53M
Book/sh-27.90
Cash/sh5.26
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees44
IPOJan 11, 2021

Ratios

P/E-
Forward P/E-
PEG-
P/S57.71
P/B-
P/C6.06
P/FCF-
EV/EBITDA-
EV/Sales48.73
Quick Ratio7.56
Current Ratio7.56
Debt/Eq-
LT Debt/Eq-
Option/ShortYes / Yes

Earnings

EPS (ttm)-46.94
EPS next Y-4.71
EPS next Q-1.04
EPS this Y51.78%
EPS next Y69.85%
EPS next 5Y48.59%
EPS past 3/5Y-27.67% 4.68%
Sales past 3/5Y-34.72% -
EPS Y/Y TTM-100.54%
Sales Y/Y TTM192.12%
EPS Q/Q-31.81%
Sales Q/Q-100.00%
EarningsNov 09 AMC
EPS/Sales Surpr.-898.28% -100.00%

Ownership

Insider Own48.17%
Insider Trans-5.43%
Inst Own74.23%
Inst Trans6.44%
ROA-402.15%
ROE-
ROIC-
Gross Margin97.99%
Oper. Margin-485.44%
Profit Margin-3878.70%
SMA2012.45%
SMA5024.82%
SMA20024.84%
Trades-

Technical

Shs Outstand12.03M
Shs Float9.88M
Short Float32.74%
Short Ratio6.06
Short Interest3.23M
52W High37.83 -15.73%
52W Low11.73 171.70%
Volatility7.80% 7.92%
ATR (14)2.45
RSI (14)60.48
Beta0.54
Rel Volume0.29
Avg Volume534.12K
Volume157,154

Performance

Perf Week0.73%
Perf Month35.60%
Perf Quarter34.34%
Perf Half Y5.77%
Perf YTD41.06%
Perf Year163.11%
Perf 3Y497.68%
Perf 5Y-77.63%
Perf 10Y-
Recom1.00
Target Price60.80
Prev Close32.64
Price31.88
Change %-2.33%

Analyst ratings

latest 8 of 8
DateActionAnalystRating changeTargetImplied
Aug 20, 2026InitiatedWWilliam BlairOutperform$51+60.0%
Apr 21, 2026InitiatedTTD CowenBuy
Feb 19, 2026InitiatedCCantor FitzgeraldOverweight$40+25.5%
Jan 30, 2025InitiatedHH.C. WainwrightBuy$32+0.4%
Jan 03, 2025UpgradeGGuggenheimNeutral → Buy$45+41.2%
Oct 11, 2021InitiatedBBofA SecuritiesBuy$11-65.5%
Sep 15, 2021InitiatedGGuggenheimBuy$20-37.3%
Sep 07, 2021InitiatedSStifelBuy$19-40.4%

Peers

Mkt cap
TickerCompanyMkt cap
EYPTEyePoint Inc30.74M
KODKodiak Sciences Inc6.87B
OCULOcular Therapeutix Inc1.47B
FDMT4D Molecular Therapeutics Inc717.62M
OTLKOutlook Therapeutics Inc117.10M
RGNXRegenxbio Inc560.06M
ANNXAnnexon Inc794.34M
AURAAura Biosciences Inc792.01M
AGMBAgomAb Therapeutics NV ADR344.26M
BLTEBelite Bio Inc ADR6.28B

Insider trading

latest 14 of 34
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
TCG Crossover GP II, LLC10% OwnerJul 22 '26Sale21.25325,0006,906,250574,047Jul 24 09:00 PM
Li YangExec. Vice President, ResearchMay 04 '26Sale33.331,58452,79917,216May 05 04:58 PM
Williams Charles OChief Operating OfficerMay 04 '26Sale33.332,03667,86616,571May 05 04:54 PM
Parker Craig CChief Executive OfficerMay 04 '26Sale33.334,524150,79816,553May 05 04:51 PM
TCG Crossover GP II, LLC10% OwnerMar 24 '26Buy24.69106,6582,633,717736,554Mar 25 08:02 PM
TCG Crossover GP II, LLC10% OwnerMar 23 '26Buy24.9015,223379,051683,225Mar 25 08:02 PM
TCG Crossover GP II, LLC10% OwnerMar 13 '26Buy24.8835,433881,463675,018Mar 16 07:05 PM
TCG Crossover GP II, LLC10% OwnerMar 12 '26Buy24.9912,374309,166657,301Mar 16 07:05 PM
TCG Crossover GP II, LLC10% OwnerMar 16 '26Buy24.991,19029,733675,613Mar 16 07:05 PM
TCG Crossover GP II, LLC10% OwnerFeb 11 '26Buy23.5717,763418,763650,567Feb 13 04:19 PM
TCG Crossover GP II, LLC10% OwnerFeb 12 '26Buy23.861,09326,082651,114Feb 13 04:19 PM
TCG Crossover GP II, LLC10% OwnerFeb 03 '26Buy21.944,35595,549641,685Feb 03 08:03 PM
TCG Crossover GP II, LLC10% OwnerJan 30 '26Buy21.394,27191,357639,141Feb 03 08:03 PM
TCG Crossover GP II, LLC10% OwnerFeb 02 '26Buy21.3873115,629639,507Feb 03 08:03 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
JSMDJanus Henderson Small/Mid Cap Growth Alpha ETFAUM: 1.04B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
IWCiShares Micro-Cap ETFAUM: 1.22B
GSSCGoldman Sachs ActiveBeta U.S. Small Cap Equity ETFAUM: 1.06B
VTWGVanguard Russell 2000 Growth Index ETFAUM: 1.41B
RSSLGlobal X Russell 2000 ETFAUM: 1.43B

News

latest 14 of 172
  • Surrozen Reports Third Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire)
  • Surrozen to Present at Upcoming Healthcare Investor Conference (GlobeNewswire) +6.90%
  • Surrozen Announces Closing of Second Tranche of March 2025 Private Placement for $95.1 Million (GlobeNewswire) +5.45%
  • Top Biotech Stock: Guggenheim Names Surrozen as Best Pick (Investing.com) +5.56%
  • Surrozen secures FDA clearance for SZN-8141 clinical trial (Clinical Trials Arena)
  • Surrozen Announces FDA Clearance of IND Application for SZN-8141 for the Treatment of Diabetic Macular Edema (GlobeNewswire)
  • Surrozen Announces Submission of IND Application for SZN-8141 for the Treatment of Diabetic Macular Edema (GlobeNewswire) -9.14%
  • Surrozen to Present at Upcoming Healthcare Investor Conferences (GlobeNewswire)
  • Surrozen Reports Second Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire) +18.39%
  • Surrozen to Present at Upcoming Healthcare Investor Conference (GlobeNewswire)
  • Surrozen to Present at Upcoming Healthcare Investor Conference (GlobeNewswire)
  • Surrozen Reports First Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire) -9.90%
  • Surrozen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
  • Surrozen (SRZN) Surges 5.9%: Is This an Indication of Further Gains? (Quartz) +6.66%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-09-11.020-1.104-11.0200.000.486
2026Q22026-08-06-0.410-1.288-0.4065.000.475
2026Q12026-05-06-11.650-1.092-11.6455.004.005
2025Q42026-03-23-19.130-1.288-23.8720.510.664
2025Q32025-11-07-8.360-1.135-8.3590.980.002
2025Q22025-08-082.550-1.1102.5530.500.002
2025Q12025-05-09-7.430-1.785-7.4340.500.002
2024Q42025-03-31-9.000-2.540-8.5960.700.001
2024Q32024-11-06-0.440-2.465-0.44410.000.002
2024Q22024-08-12-7.990-2.790-7.9890.000.001
2024Q12024-05-08-4.240-4.250-4.2390.000.001
2023Q42024-03-21-4.380-3.000-4.3200.000.002
2023Q32023-11-08-5.100-4.425-5.1370.000.002
2023Q22023-08-09-4.650-6.150-4.6820.000.002
2023Q12023-05-10-7.200-5.250-7.1560.000.004
2022Q42023-03-22-0.450-6.408-0.38612.500.004

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2021FY-33.150-36.500-23.3980.000.00
2022FY-15.600-21.554-15.55412.500.00
2023FY-21.330-18.225-21.3290.000.00
2024FY-21.670-14.940-21.67210.6610.00
2025FY-32.370-8.763-32.3703.482.29
2026FY--15.610--10.20
2027FY--4.707--0.80
2028FY--4.398--0.87
2029FY--4.748--0.87
2030FY--4.990--2.45

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-104010.250.001.00
2026Q4S2026-11-094100.480.001.00
2026Q4S2026-09-234100.480.001.00
2026Q4S2026-08-074000.470.001.00
2026Q4S2026-07-214000.470.001.00
2026Q4S2026-06-024010.470.001.00
2026Q4S2026-05-074110.470.001.00
2026Q4S2026-05-044200.480.001.00
2026Q4S2026-04-204110.470.001.00
2026Q4S2026-03-243110.620.001.00
2026Q4S2026-02-183000.330.000.98
2026Q4S2025-11-112000.000.000.00
2026Q4S2025-11-102000.000.000.00
2026Q4S2025-11-091000.000.000.00

Estimate history

EPS, annual-41.121-23.398-15.554-21.329-21.672-32.365-46.9409
Period202020212022202320242025TTM
EPS, quarterly-0.444-8.596-7.4342.553-8.359-23.872-11.645-0.406-11.018
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual0012.5010.6553.47710.53
Period202020212022202320242025TTM
Sales, quarterly100.6550.9830.9830.9830.528550
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual0.7962.3362.0062.0633.2629.77512.028
Period202020212022202320242025MRQ
Shares, quarterly3.253.2628.4958.578.5719.77511.4911.75412.028
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY
Total Revenue10.533.4810.650.0012.500.000.00
Cost of Goods Sold Incl. D&A0.210.541.441.913.273.302.93
Gross Profit10.322.949.21-1.919.23-3.30-2.93
Selling, General and Administrative Excl. Other61.4245.0334.7541.1253.5751.0929.88
Research and Development37.4328.8319.6925.3233.7436.8822.75
Other Operating Expense0.000.000.000.000.000.000.00
Operating Income-51.11-42.09-25.54-43.03-44.34-54.39-32.81
Interest Expense0.000.000.000.000.000.000.00
Unusual Expense224.10203.2238.232.54-7.890.331.58
Net Income Before Taxes-390.21-242.03-63.56-43.04-36.00-54.65-32.72
Income Taxes0.000.000.000.000.000.000.00
Consolidated Net Income-408.35-242.03-63.56-43.04-36.00-54.65-32.72
Net Income From Continuing Operations-408.35-242.03-63.56-43.04-36.00-54.65-32.72
Net Income-408.35-242.03-63.56-43.04-36.00-54.65-32.72
EPS (Recurring)-24.88-13.34-12.55-20.45-17.94-23.30-41.12
EPS (Basic, Before Extraordinaries)-43.79-32.37-21.67-21.33-15.55-23.40-41.12
EPS (Diluted)-46.94-32.37-21.67-21.33-15.55-23.40-41.12
EBITDA-50.90-41.55-24.10-41.12-41.07-51.09-29.88
Non-Operating Income (Expense)-115.013.290.202.530.450.070.09
Other After Tax Adjustments-18.140.000.000.000.000.000.00
Stock Option Compensation Expense8.933.834.114.374.522.320.64
Price To Sales Ratio35.9948.613.95-1.62--
Gross Margin97.9984.5686.47-73.85--
Operating Margin-485.44-1,210.58-239.69--354.71--
Net Margin-3,878.70-6,960.77-596.56--288.03--
Shares Outstanding12.039.783.262.062.012.340.80
Market Capitalization374.70374.7046.6319.1620.44225.62237.14

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.005.005.000.530.980.980.980.66
Cost of Goods Sold Incl. D&A0.050.050.070.040.060.140.290.32
Gross Profit-0.054.954.930.480.920.850.690.33
Selling, General and Administrative Excl. Other17.5915.3215.3913.1211.819.8610.248.93
Research and Development10.798.439.268.957.715.916.265.03
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-17.64-10.37-10.46-12.64-10.88-9.02-9.55-8.59
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense73.85-39.2576.86112.6440.75-31.5255.7019.68
Net Income Before Taxes-129.7250.18-127.50-183.16-71.6439.75-26.97-28.04
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-129.7232.04-127.50-183.16-71.6421.81-26.97-28.04
Net Income From Continuing Operations-129.7232.04-127.50-183.16-71.6421.81-26.97-28.04
Net Income-129.7232.04-127.50-183.16-71.6421.81-26.97-28.04
EPS (Recurring)-6.63-1.59-6.73-11.46-5.03-0.033.31-4.37
EPS (Basic, Before Extraordinaries)-11.022.75-11.65-23.87-8.362.55-7.43-8.60
EPS (Diluted)-11.02-0.41-11.65-23.87-8.362.55-7.43-8.60
EBITDA-17.59-10.32-10.39-12.59-10.82-8.88-9.26-8.27
Non-Operating Income (Expense)-38.2321.30-40.19-57.88-20.0117.2438.280.23
Other After Tax Adjustments0.00-18.140.000.000.00-17.940.000.00
Stock Option Compensation Expense2.932.892.101.001.000.990.830.90
Price To Sales Ratio35.9952.1842.5659.1430.646.053.634.39
Gross Margin-98.9898.7091.4893.9086.0670.0950.84
Operating Margin--207.40-209.12-2,393.75-1,107.32-917.29-971.62-1,311.76
Net Margin-640.76-2,550.10-34,689.20-7,288.202,218.51-2,743.64-4,280.76
Shares Outstanding12.0311.7511.499.788.578.578.493.26
Market Capitalization374.70301.29334.61193.71110.4376.5537.8946.63

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY
Cash & Short Term Investments89.2534.5636.0475.84101.8549.18
Short Term Receivables0.212.542.151.980.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets2.111.832.943.493.341.04
Total Current Assets91.5638.9341.1381.31105.1950.22
Net Property, Plant & Equipment6.438.363.866.909.3811.39
Total Investments and Advances0.690.840.690.4122.060.41
Intangible Assets-----0.00
Other Assets0.050.330.400.830.550.04
Total Assets98.7348.4746.0889.44137.1762.06
Short Term Debt Incl. Current Port. of LT Debt1.291.832.502.232.192.11
Accounts Payable0.730.310.530.660.000.00
Other Current Liabilities7.915.184.136.8511.385.17
Total Current Liabilities9.937.327.159.7313.577.28
Long Term Debt5.356.640.883.385.607.49
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities271.2155.890.120.338.300.00
Total Liabilities286.4969.858.1413.4327.4714.77
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity-187.76-21.3837.9476.00109.7047.29
Total Shareholders Equity-187.76-21.3837.9476.00109.7047.29
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity-187.76-21.3837.9476.00109.7047.29
Total Liabilities & Stockholders Equity98.7348.4746.0889.44137.1762.06
Book Value Per Share-19.21-6.5518.3937.8946.9759.44
Tangible Book Value Per Share-19.21-6.5518.3937.8946.9759.44
Full-Time Employees44414274833
Price to Book Ratio-1.148.230.420.262.061.92
Return on Assets-328.86-134.46-63.52-31.78-47.32-
Return on Equity--767.91-75.55-38.78-55.60-
Return on Invested Capital---110.88-45.36-47.40-59.72
Quick Ratio9.225.325.758.357.756.90
Current Ratio9.225.325.758.357.756.90

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY
Net Income-390.21-242.03-63.56-43.04-36.00-54.65-32.72
Depreciation0.210.541.441.913.273.302.93
Other Funds (Non Cash)353.58208.0945.334.70-2.992.760.64
Funds from Operations-36.42-33.40-16.79-36.43-35.73-48.59-29.15
Extraordinary Item0.000.000.000.000.000.000.00
Changes in Working Capital5.873.15-0.84-3.93-8.42-0.220.05
Cash from Operating Activities-30.55-30.24-17.63-40.36-44.15-48.81-29.10
Capital Expenditures-0.23-0.13-0.03-0.40-0.73-1.27-0.87
Net Assets From Acquisitions0.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.0052.1239.04-76.44-14.20
Purchase of Investments0.000.000.00-28.04-29.60-91.74-14.20
Sale Or Maturity of Investments0.000.000.0080.1768.6415.300.00
Other Uses0.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.00
Cash from Investing Activities-0.23-0.13-0.0351.7238.31-77.71-15.07
Cash Dividends Paid0.000.000.000.000.000.000.00
Change in Capital Stock49.7485.0516.180.28-2.48124.6350.05
Repurchase of Common Pref Stock0.000.000.00-0.06-2.62-0.00-0.00
Sale of Common Pref Stock49.7485.0516.180.340.14124.6350.05
Proceedsfrom Stock Options110.8583.780.000.000.00124.2249.89
Issuance or Reduction of Debt, Net0.000.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.00-0.090.000.00
Other Financing Activities Uses0.000.000.000.00-0.090.000.00
Cash from Financing Activities49.7485.0516.180.28-2.56124.6350.05
Net Change in Cash18.9654.68-1.4811.64-8.40-1.895.88
Free Cash Flow-30.77-30.37-17.65-40.76-44.87-50.08-29.97
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments100.35102.04106.9189.2581.3390.39
Short Term Receivables0.005.005.000.212.572.57
Inventories0.000.000.000.000.000.00
Other Current Assets2.532.362.042.111.961.28
Total Current Assets102.89109.40113.9591.5685.8694.23
Net Property, Plant & Equipment5.085.566.046.436.597.08
Total Investments and Advances0.640.640.690.691.531.30
Other Assets0.430.010.030.050.060.08
Total Assets109.03115.61120.7198.7394.05102.70
Short Term Debt Incl. Current Port. of LT Debt2.051.991.931.291.241.20
Accounts Payable0.651.070.890.730.540.35
Other Current Liabilities10.915.956.757.914.754.19
Total Current Liabilities13.619.019.569.936.535.74
Long Term Debt3.794.334.855.355.846.32
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities427.26320.93384.44271.21105.1943.52
Total Liabilities444.66334.27398.86286.49117.5655.58
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity-335.62-218.66-278.15-187.76-23.5247.11
Total Shareholders Equity-335.62-218.66-278.15-187.76-23.5247.11
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity-335.62-218.66-278.15-187.76-23.5247.11
Total Liabilities & Stockholders Equity109.03115.61120.7198.7394.05102.70
Book Value Per Share-27.90-18.60-24.21-19.21-2.745.50
Tangible Book Value Per Share-27.90-18.60-24.21-19.21-2.745.50
Full-Time Employees---44--
Price to Book Ratio-1.14-1.07-1.52-8.242.3413.38
Return on Assets-402.15-320.90-306.11-353.23-147.62-46.88
Return on Equity------130.27
Return on Invested Capital-----40.82
Quick Ratio7.5612.1411.919.2213.1516.41
Current Ratio7.5612.1411.919.2213.1516.41

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-129.7250.18-127.50-183.16-71.6439.75
Depreciation0.050.050.070.040.060.14
Other Funds (Non Cash)116.37-56.26120.52172.9562.90-46.52
Funds from Operations-13.30-6.04-6.92-10.17-8.69-6.64
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital8.47-1.38-5.584.36-0.350.53
Cash from Operating Activities-4.83-7.42-12.49-5.81-9.04-6.11
Capital Expenditures-0.03-0.02-0.12-0.06-0.02-0.02
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-0.03-0.02-0.12-0.06-0.02-0.02
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock3.172.5130.2813.780.01-5.12
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock3.172.5130.2813.780.01-5.12
Proceedsfrom Stock Options0.000.2126.8683.780.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities3.172.5130.2813.780.01-5.12
Net Change in Cash-1.69-4.9217.667.91-9.05-11.26
Free Cash Flow-4.86-7.43-12.62-5.87-9.06-6.13

Revenue breakdown

Collaboration and license revenue2024: 10.00M
Research service revenue2024: 655.00K 2025: 3.48M
Consolidation, Policy2024: -45.00K 2025: -23.00K
Germany2024: 10.00M
United States2024: 700.00K 2025: 3.50M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3053.12%3.2M6.1M544.47K
2026-10-1551.42%3.1M6.1M527.03K
2026-09-3035.96%2.2M6.1M445.01K
2026-09-1536.05%2.2M6.1M219.21K
2026-08-3123.74%1.4M6.1M204.98K
2026-08-1420.58%1.3M6.1M191.15K
2026-07-3119.27%1.2M6.0M163.50K
2026-07-1517.43%1.0M5.6M132.44K
2026-06-3012.74%0.7M5.6M130.67K
2026-06-156.21%0.3M5.6M104.47K
2026-05-299.89%0.6M5.6M106.09K
2026-05-159.79%0.5M5.6M100.03K
2026-04-3010.81%0.6M5.2M103.02K
2026-04-158.37%0.4M5.2M116.75K
2026-03-3110.56%0.3M3.3M107.24K
2026-03-1313.35%0.3M2.4M108.00K
2026-02-2711.83%0.3M2.4M112.66K
2026-02-1311.44%0.3M2.4M114.77K
2026-01-309.01%0.2M2.7M122.28K
2026-01-155.42%0.2M4.0M89.05K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call10.0021.2024.500.009.2240.000.000.974-0.0800.003
call12.5018.7022.000.007.6150.000.000.968-0.0790.004
call15.0016.2019.5014.306.3810.000.000.957-0.0860.004
call17.5013.7017.000.005.3750.000.000.940-0.0990.006
call20.0011.2014.500.004.5180.000.000.927-0.0950.007
call22.508.8012.000.003.7630.000.000.899-0.1020.009
call25.006.409.504.003.0797.000.000.861-0.1050.011
call30.002.703.603.221.32240.000.000.656-0.1390.018
call35.000.551.501.701.3414.004.000.367-0.1430.019
call40.000.000.750.001.5110.000.000.200-0.1190.014
call45.000.000.555.051.7921.000.000.137-0.1110.011
call50.000.000.554.952.1501.000.000.120-0.1210.010
put10.000.000.300.005.7820.000.00-0.041-0.1420.004
put12.500.000.300.204.7742.000.00-0.051-0.1400.005
put15.000.000.350.053.9681.000.00-0.062-0.1370.006
put17.500.000.450.903.2923.000.00-0.076-0.1320.007
put20.000.000.450.002.7050.000.00-0.092-0.1250.008
put22.500.000.550.302.0091790.00-0.101-0.0990.009
put25.000.000.650.951.64263.000.00-0.139-0.1020.011
put30.000.701.701.201.3276.001.00-0.344-0.1360.018
put35.003.404.608.201.3481.000.00-0.633-0.1390.019
put40.006.508.9012.001.5617.000.00-0.800-0.1150.014
put45.0011.0014.300.002.3710.000.00-0.841-0.1250.012
put50.0015.9019.700.003.0450.000.00-0.860-0.1370.011

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-0910-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-098-KCurrent report2026-11-09SEC
2026-11-06SCHEDULE 13D/ASEC
2026-10-224Statement of changes in beneficial ownership of securities2026-10-20SEC
2026-10-22SCHEDULE 13D/ASEC
2026-10-224Statement of changes in beneficial ownership of securities2026-10-20SEC
2026-10-208-KCurrent report2026-10-20SEC
2026-10-07SCHEDULE 13G/ASEC
2026-10-028-KCurrent report2026-10-02SEC
2026-10-01SCHEDULE 13GSEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-14SCHEDULE 13GSEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-11SCHEDULE 13G/ASEC
2026-08-0725-NSESEC
2026-08-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-068-KCurrent report2026-08-06SEC
2026-07-24SCHEDULE 13G/ASEC
2026-07-244Statement of changes in beneficial ownership of securities2026-07-22SEC
2026-06-164Statement of changes in beneficial ownership of securities2026-06-15SEC
2026-06-164Statement of changes in beneficial ownership of securities2026-06-15SEC
2026-06-164Statement of changes in beneficial ownership of securities2026-06-15SEC
2026-06-164Statement of changes in beneficial ownership of securities2026-06-15SEC
2026-05-194Statement of changes in beneficial ownership of securities2026-05-13SEC
2026-05-18SCHEDULE 13D/ASEC
2026-05-15SCHEDULE 13G/ASEC
2026-05-15SCHEDULE 13G/ASEC
2026-05-15SCHEDULE 13GSEC
2026-05-15SCHEDULE 13G/ASEC
2026-05-15SCHEDULE 13G/ASEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-07006.91M1
2026-060000
2026-0500271.46K3
2026-040000
2026-034.23M500
2026-02556.02K400
2026-012.69M1353.32K2
2025-121.39M400
2025-117.98M200

Institutional holders

Manager% owned
Column Group LLC16.51%
TCG Crossover Management, LLC12.69%
Boxer Capital Management, LLC9.52%
Kalehua Capital Management LLC6.64%
MILLENNIUM MANAGEMENT LLC5.88%
Point72 Asset Management, L.P.5.72%
Venrock Adviser, LLC5.45%
STEMPOINT CAPITAL LP5.19%
PERCEPTIVE ADVISORS LLC4.34%
Spruce Street Capital LP3.72%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND2.43%
iShares Russell 2000 ETF1.39%
VANGUARD EXTENDED MARKET INDEX FUND0.89%
Fidelity Small Cap Index Fund0.69%
iShares Russell 2000 Growth ETF0.54%
Fidelity Extended Market Index Fund0.36%
VANGUARD RUSSELL 2000 INDEX FUND0.36%
iShares Micro-Cap ETF0.20%
Schwab Small-Cap Index Fund0.16%
Fidelity Total Market Index Fund0.14%

OakChart. SRZN. Cached 15 minutes.